American company Moderna announced Monday that it has filed emergency leave requests for the covid-19 vaccine in the United States. and in Europe, confirmed its high efficacy after full results (94.1%).
Two weeks after announcing an efficacy of 94.5% according to preliminary results, Moderna reported that 185 of the 196 participants infected with COVID-19 in its clinical study belonged to the placebo group and 11 to the vaccinated group. The calculated efficiency of 94.1%. No serious form of the disease was noted in the vaccinated group.
The laboratory has both coronavirus vaccine. United States Food and Drug Administration (FDA) and European Medicines Agency. Regulators will decide whether it is safe and effective enough to analyze the mRNA vaccine test data and recommend its administration.